Skip to main content

schizophrenia Archives

Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment

Jan. 8, 2018—Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.

Read more

Health and Medicine Healthcare Solutions Reporter Research Strategic Plan


Vanderbilt begins Phase 1 trials of new Alzheimer’s drug

Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.

Read more

Health and Medicine Healthcare Solutions myVU myVU News Reporter Research Strategic Plan


Investigational new drug for Alzheimer’s scheduled for first study in humans

Dec. 27, 2016—Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.

Read more

Health and Medicine Reporter Research


Researchers eye potential schizophrenia ‘switch’

Sep. 15, 2016—Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice.

Read more

Health and Medicine Reporter Research


Foundation’s support speeds search for new schizophrenia drugs at Vanderbilt

Aug. 15, 2016—Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation.

Read more

Health and Medicine Reporter Research


Putting schizophrenia to bed

Mar. 21, 2016—A new compound developed at Vanderbilt treats multiple symptoms of schizophrenia in an animal model, without causing sedation.

Read more

Health and Medicine Reporter Research


Brain circuitry in psychosis

Aug. 21, 2015—Functional magnetic resonance imaging has revealed faulty circuits between the thalamus – a central hub of brain activity – and other brain regions.

Read more

Health and Medicine Reporter Research


Signals of schizophrenia

Jul. 9, 2015—Vanderbilt researchers have discovered a possible molecular mechanism of schizophrenia that could lead to new treatments for the disorder.

Read more

Health and Medicine Healthcare Solutions Reporter Research Strategic Plan


A little jolt helps the brain get back on track

Jul. 8, 2015—Applying mild electrical stimulation to an area of the brain associated with cognitive control helps people with schizophrenia to recognize errors and adjust their behavior to avoid them.

Read more

Education and Psychology Healthcare Solutions myVU myVU News Research Strategic Plan Trans-institutional Programs


A view of brain function in disease

Jun. 16, 2015—Vanderbilt investigators report the first use of a specialized type of MRI to study the hippocampus in patients with schizophrenia.

Read more

Health and Medicine Reporter Research


Findings reveal new target in quest to ease schizophrenia

May. 7, 2015—Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans.

Read more

Health and Medicine Reporter Research


Multi-sensory processing model explores autism, schizophrenia

Mar. 19, 2015—There is growing evidence that disorders such as autism and schizophrenia involve deficits in what is called “multi-sensory processing,” the ability of the brain to properly integrate information coming in through the eyes, ears and other senses.

Read more

Health and Medicine Reporter Research


Page 1 of 41234